Kate Van Brunt
Overview
Explore the profile of Kate Van Brunt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Eby E, Van Brunt K, Brusko C, Curtis B, Lage M
Clin Ther
. 2015 Sep;
37(10):2297-2308.e1.
PMID: 26341171
Purpose: The purpose of this study was to examine costs, resource use, adherence, and hypoglycemic events among patients with type 2 diabetes mellitus (T2DM) treated with increasing doses of 100-U/mL...
12.
Eby E, Van Brunt K, Brusko C, Curtis B, Lage M
Clin Interv Aging
. 2015 Jul;
10:991-1001.
PMID: 26124652
Objective: To examine costs, resource utilization, adherence, and hypoglycemic events among various doses of U-100 insulin regimens among elderly patients (age ≥65 years) diagnosed with diabetes. Methods: Truven Health Analytics...
13.
Matfin G, Van Brunt K, Zimmermann A, Threlkeld R, Ignaut D
J Diabetes Sci Technol
. 2015 Apr;
9(5):1071-9.
PMID: 25901022
Background: This 4-week, phase 3b, multicenter, open-label, single-arm, outpatient study demonstrated the safe and effective use of the dulaglutide single-dose pen containing 0.5 mL of placebo for subcutaneous injection in...
14.
Van Brunt K, Curtis B, Brooks K, Heinloth A, Castro R
J Am Med Dir Assoc
. 2013 Nov;
14(11):809-16.
PMID: 24176598
Objective: To summarize currently available data about insulin therapy in patients with diabetes mellitus (DM), focusing on patients with type 2 DM (T2DM), in long term care (LTC) settings. Data...
15.
Matza L, Cong Z, Chung K, Stopeck A, Tonkin K, Brown J, et al.
Patient Prefer Adherence
. 2013 Sep;
7:855-65.
PMID: 24039408
Introduction: Although cost-utility models are often used to estimate the value of treatments for metastatic cancer, limited information is available on the utility of common treatment modalities. Bisphosphonate treatment for...
16.
Matza L, Chung K, Van Brunt K, Brazier J, Braun A, Currie B, et al.
Eur J Health Econ
. 2013 Jan;
15(1):7-18.
PMID: 23355121
Introduction: Patients with bone metastases often experience skeletal-related events (SREs). Although cost-utility models are used to examine treatments for metastatic cancer, limited information is available on utilities of SREs. The...
17.
Matza L, Fallowfield L, Chung K, Currie B, Van Brunt K, Patrick D
Support Care Cancer
. 2012 Feb;
20(4):657-77.
PMID: 22302082
Purpose: When treating metastatic bone disease, relief of bone pain is often a key outcome. Because pain cannot be quantified with objective clinical measures, patient-reported outcome (PRO) measures are required...
18.
Van Brunt K, Matza L, Classi P, Johnston J
Patient Prefer Adherence
. 2011 Feb;
5:33-43.
PMID: 21311700
Objectives: A growing body of literature has highlighted the importance of considering patient preferences as part of the medical decision-making process. The purpose of the current review was to identify...
19.
Boye K, Matza L, Walter K, Van Brunt K, Palsgrove A, Tynan A
Eur J Health Econ
. 2010 Mar;
12(3):219-30.
PMID: 20224930
Introduction: Although cost-utility models are frequently used to estimate treatment outcomes for type 2 diabetes, utilities are not available for key attributes of injectable treatments. The purpose of this study...